Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Lilly and Boehringer Ingelheim amend Yentreve/AriClaim agreements

Feb. 17, 2006

Phase I study of lemuteporfin in BPH fails to meet primary efficacy objective

Feb. 16, 2006

Generic name bremelanotide approved for PT-141

Feb. 10, 2006

Protection for gentamicin-evoked nephrotoxicity / News in Context

Feb. 10, 2006

Enrollment completed in phase II stress urinary incontinence study of cizolirtine

Feb. 2, 2006

AEterna Zentaris regains rights to cetrorelix for BPH

Feb. 1, 2006

Recent Tanabe patent reports new treatments for urological disorders

Feb. 1, 2006

Novel nonsteroidal selective 5alpha-reductase type 2 inhibitor presented

Jan. 27, 2006

Erectile dysfunction medications may be associated with increased risk of optic nerve damage

Jan. 26, 2006

Japanese approval for Urief

Jan. 24, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...